Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

Inclusion Criteria: * Subject must have histologically confirmed oral proliferative verrucous leukoplakia (OPVL), as defined by: multifocal lesions (≥ 2) or contiguous lesions ≥ 3 cm or a single lesion ≥ 4 cm in largest diameter (at least one lesion with any degree of dysplasia). (Note: no restriction on the length of time that patients have had one or more existing lesions) * Willing to provide blood and tissue from diagnostic biopsies * Any smoking history is permitted. A history of prior or current tobacco use is not an exclusion criteria. While discouraged, patients are permitted to continue tobacco use while on the study. * Age 18 years or older * ECOG performance status ≤ 2 (Karnofsky ≥60%, see Appendix A) * Participant must have normal organ and marrow function as defined below within 21 days prior to study registration: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,000/mcL * platelets ≥100,000/mcL * total bilirubin ≤2.0 g/dL * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal * Ability to understand and the willingness to sign a written informed consent document * Women of childbearing potential (WOCBP) must agree to use appropriate method(s) of contraception. WOCBP should plan to use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for niv…